Q1 2026 Preliminary Results: Operating Profit Down, Net Income Up
-
Separate sales ₩335.7B (+6.2% YoY), operating profit ₩27.4B (-34.7% YoY)
-
Separate net profit ₩35.1B (+20.3% YoY), pre-tax profit ₩43.2B (+26.8% YoY)
-
Consolidated sales ₩377.8B, operating profit ₩22.2B, net profit ₩25.5B
-
Preliminary unaudited figures, subject to change
KOSPI Filing Information
-
Filing: Preliminary Operating Results (Fair Disclosure)
-
Company: Daewoong Pharma (069620)
-
Submission: Daewoong Pharma
-
Receipt: 05-12-2026
-
Under KRX KOSPI Market Division